<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175092">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816400</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP187</org_study_id>
    <nct_id>NCT00816400</nct_id>
  </id_info>
  <brief_title>A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.</brief_title>
  <acronym>MEDI-575</acronym>
  <official_title>A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRα), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult
      subjects with advanced solid tumors refractory to standard therapy or for which no standard
      therapy exists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of MEDI-575 and to determine the maximum tolerated dose in this subject population.</measure>
    <time_frame>30 days after the last dose of MEDI-575.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess of PK, IM, and antitumor activity.</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and/or optimal biologic does of MEDI-575 in adult subjects with advanced solid tumors.</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-575 (Dose escalation and Dose Expansion Cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-575</intervention_name>
    <description>Administered at a dose determined by the subjects enrollment cohort as a 60 or 90 min. IV infusion as part of a 21 day treatment cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced solid tumor for which no curative or standard
             therapies exist

          -  Karnofsky performance status of ≥ 60

          -  Life expectancy of &gt;12 weeks

          -  Adequate hematologic and organ function

          -  Negative serum pregnancy test (women only)

          -  Two methods of birth control for female participants of child-bearing potential or
             male participants with their female partners of child-bearing potential

        Exclusion Criteria:

          -  Prior chemotherapy or investigational treatment within 4 weeks of study drug
             administration

          -  Prior biological or immunological treatment within 6 weeks of study drug
             administration

          -  Concurrent therapy for of cancer

          -  Major surgery within four weeks or minor surgery within two weeks of study drug
             administration

          -  History of diabetes or current treatment for diabetes

          -  New York Heart Association ≥ Grade 2 congestive heart failure

          -  History of myocardial infarction, unstable angina, transient ischemic attack or
             stroke within the previous 6 months prior to study entry

          -  History of other invasive malignancy within 5 years (exceptions are cervical
             carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ
             of the breast that are surgically cured)

          -  Significant active infection

          -  Known brain metastases

          -  Pregnancy or lactation or plans to become pregnant while on study

          -  Clinically significant abnormality on ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sikorski, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 10, 2012</lastchanged_date>
  <firstreceived_date>December 23, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
